Beijing Continent enrolls the first subject of pirfenidone capsules Phase III clinical trial for pneumoconiosis
We are pleased to announce that our group company, Beijing Continent Pharmaceutical Co., Ltd., has announced that the first subject in Phase III clinical trial of the pirfenidone capsule (F647), a treatment for pneumoconiosis, has been enrolled. For more details, please see the article dated June 10, 2022 on the Beijing Continent's website below.
(Please note that currently only Chinese version is available. Thank you for your understanding.)